A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
NCT07071519
Recruiting
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine). This study will assess how Risankizumab moves through the body as well as how safe and effective it is in treating pediatric participants with moderate to severely active UC. Adverse events and change in disease activity will be assessed. Risankizumab is an approved medication for moderate to severe UC in multiple countries and is being... Read More
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
08/12/2025
Locations: Childrens Center For Digestive Health Care /ID# 273228, Atlanta, Georgia +2 locations
Conditions: Ulcerative Colitis
Register for Updates
A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes
NCT07112872
Recruiting
This multicenter, randomized, double-blind, placebo- and open-label active comparator-controlled, parallel-group, dose-range-finding, Phase II study aims to evaluate the efficacy, tolerability, and safety of RO7795081 for glycemic control in adult participants with Type 2 diabetes mellitus (T2D).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Emerson Clinical Research Institute, Washington, District of Columbia +5 locations
Conditions: Type 2 Diabetes Mellitus
Register for Updates
Home Blood Transfusions
NCT07121140
Recruiting
This is a pilot single arm study to evaluate the feasibility and acceptability of a home blood transfusion program. Patients will be enrolled with hematologic malignancies and other bone marrow failure syndromes who are transfusion dependent and interested in a home blood transfusion program. Participants enrolled in the study will receive 1-5 units of blood products at home. Data on barriers to administration will be recorded. Surveys and qualitative interviews will be completed to better under... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
Conditions: Hematologic Malignancy, Myelodysplastic Syndromes, Acute Myeloid Leukemia, Transfusion Dependent Cytopenias
Register for Updates
A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
NCT06698796
Recruiting
The purpose of this study is to understand how the study medicine, dazukibart, works in people with active idiopathic inflammatory myopathies (dermatomyositis \[DM\] or polymyositis \[PM\]). Idiopathic inflammatory myopathies are a group of disorders that show inflammation of the muscles used for movement. There are several types of idiopathic inflammatory myopathies, including DM and PM. DM and PM involve weakness of the muscles closest to the center of the body, such as the muscles of the hi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Glendale, Glendale, Arizona +8 locations
Conditions: Dermatomyositis, Polymyositis
Register for Updates
WORTH Paths Intervention
NCT06889831
Recruiting
Women in the criminal legal system are more likely to experience substance use disorders and unintended pregnancy than women in the general public. However, they often face barriers to accessing substance use treatment and sexual and reproductive health services. This study tests the feasibility and acceptability of Women on the Road to Health (WORTH) Promoting Access to Treatment, Health, and Support (Paths), a digital intervention adapted from the evidence-based CDC Best Practice HIV preventi... Read More
Gender:
FEMALE
Ages:
Between 18 years and 44 years
Trial Updated:
08/12/2025
Locations: Fairleigh Dickinson University, Teaneck, New Jersey
Conditions: Substance Use Disorder (SUD), Sexual and Reproductive Health, Sexual Risk Behavior
Register for Updates
Remote Vinyasa Yoga Program for Heart Health
NCT06961981
Recruiting
The purpose of this study is to test a 12-week vinyasa yoga (flow yoga) intervention via Zoom. This program will be for 30 individuals with high blood pressure. 15 will receive the intervention and 15 will follow their usual routine. The investigators will determine if this vinyasa yoga program is feasible and acceptable in this population. Investigators will measure and compare blood pressure and other health responses such as physical health and well-being before and after participants complet... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/12/2025
Locations: West Virginia University, Morgantown, West Virginia
Conditions: Hypertension, Cardiovascular Diseases
Register for Updates
VIZ ACCESS HCM - Multi-Site Registry
NCT07103057
Recruiting
To describe the clinical, economic, and population characteristics of newly diagnosed, previously diagnosed, and suspected patients evaluated by Viz HCM. HCM is underdiagnosed in the community and AI algorithms have been developed as screening tools. However, it is not well understood how to best integrate AI screening tools and their potential impact.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Emory University, Atlanta, Georgia +2 locations
Conditions: Hypertrophic Cardiomyopathy
Register for Updates
Temporal Investigation of Multimodal Elements
NCT07107386
Recruiting
The TIME Study is a research project aiming to understand the body's natural rhythms. The goal is to see how daily and weekly changes in our bodies-from what's happening at a molecular level to data from wearable devices-are connected. What is the study about? This study is trying to create a detailed map of how a person's body changes over time. By looking at information from blood, urine, and other samples, as well as data from smartwatches and other devices, researchers want to learn how our... Read More
Gender:
ALL
Ages:
55 years and above
Trial Updated:
08/12/2025
Locations: Buck Institute, Novato, California
Conditions: Health
Register for Updates
VK2735 for Weight Management Phase 3
NCT07104500
Recruiting
This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) with one or more weight related comorbid condition without Type 2 Diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Viking Clinical Site #1037, Birmingham, Alabama +120 locations
Conditions: Weight Loss
Register for Updates
Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants
NCT07093580
Recruiting
The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics (PK) of single- and multiple-dose administration of S-892216-LAI in healthy adults.
Gender:
MALE
Ages:
Between 18 years and 55 years
Trial Updated:
08/12/2025
Locations: ICON Clinical Research: Lenexa, Lenexa, Kansas +1 locations
Conditions: Healthy Participants
Register for Updates
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT06907615
Recruiting
The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: MD Anderson Cancer Hospital, Houston, Texas +1 locations
Conditions: Non Small Cell Lung Cancer
Register for Updates
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
NCT06780137
Recruiting
Researchers are looking for new ways to treat people with extensive-stage small cell lung cancer (SCLC) that has relapsed or is refractory. Gocatamig is a new type of immunotherapy that uses a person's immune system to find and destroy cancer cells. Ifinatamab deruxtecan (also known as I-DXd) is a drug which binds to a specific target on cancer cells and delivers treatment to destroy those cells. Durvalumab is a different type of immunotherapy that also destroys cancer cells. Researchers want to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: University of Chicago ( Site 1108), Chicago, Illinois +24 locations
Conditions: Small Cell Lung Cancer
Register for Updates